Integrating recovery with daily life

Vision & Mission

Our Vision

We aim to become the global leader in stroke recovery by redefining what is possible in neurorehabilitation.

Through advanced closed-loop neuromodulation, we are setting a new standard of care — enabling stroke survivors to integrate recovery into their daily life so they can regain independence, restore mobility, and achieve outcomes previously considered unattainable. Our vision is not incremental improvement. It is category leadership in a multi-billion-dollar market with significant unmet need.

Our Mission

We develop next-generation implantable neuromodulation devices that aim to enhance recovery by driving targeted neuroplasticity.

By pairing intelligent stimulation with rehabilitation, we aspire to unlock measurable functional gains beyond conventional therapy alone. Our mission is to bring this technology to patients at scale. We are executing pivotal clinical trials, advancing toward FDA approval, and expanding manufacturing to support commercial launch.

Through disciplined clinical execution, regulatory strategy, and supply chain control, we are building a capital-efficient platform positioned for rapid market penetration and long-term value creation.

Technology

NeuWire is developing a next-generation, closed-loop Vagus Nerve Stimulation (VNS) platform designed to restore function after neurological injury.

At the core of the system is a miniature implant that is about 50 times smaller than traditional VNS devices and is placed through a single, minimally invasive outpatient procedure. The device has no implanted battery and is wirelessly powered and controlled by an external module, simplifying surgery and improving patient comfort.

What makes NeuWire different is its closed-loop approach. Stimulation is delivered only when the patient performs high-quality therapeutic movements, using a patented dynamic algorithm that adjusts in real time. By pairing rehabilitation with precisely timed vagus nerve stimulation, the system aims to reinforce active neural circuits and to promote targeted neuroplasticity, helping the brain and spinal cord rewire more effectively.

This combination of minimally invasive hardware, intelligent stimulation, and scalable in-clinic and at-home therapy positions NeuWire to lead the next generation of neurorehabilitation technology.

Intelligent in-clinic and at-home rehabilitation

Who can benefit

NeuWire’s closed-loop neuromodulation platform targets one of the largest and most underserved patient populations in healthcare: stroke survivors living with chronic motor deficits. Each year, approximately 800,000 people experience a stroke in the United States alone, with over 6 million survivors currently living with long-term disability. More than half of these individuals suffer reduced mobility that limits independence, employability, and quality of life.

Our technology is designed for patients who have plateaued with conventional rehabilitation and need a therapy that actively drives neuroplasticity rather than passively supports recovery. By integrating implantable stimulation with in-clinic and at-home rehabilitation, NeuWire addresses both early and chronic stroke populations — creating access to a large, durable, and reimbursable market with significant unmet clinical need.

0k

People who experience a stroke each year

+0M

Survivors

>0%

Percentage of these individuals who suffer from reduced mobility

FINANCIALS

NeuWire is now opening its Series-A financing round to fund the FDA Investigational Device Exemption (IDE) pivotal clinical study required for regulatory approval and commercial launch.

This capital will support execution of the multi-year trial, regulatory advancement, manufacturing scale-up, and preparation for market entry. Successful completion of the IDE study will position NeuWire to obtain FDA approval, unlock reimbursement pathways, and transition from a clinical-stage company to a revenue-generating medical device platform.